Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

导出 OA

翻译打印收藏纠错

第一作者： Giulia,Falconi

第一单位： Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy.

作者： Giulia,Falconi ^[1] ; Emiliano,Fabiani ^[1] ; Alfonso,Piciocchi ^[2] ; Marianna,Criscuolo ^[3] ; Luana,Fianchi ^[3] ; Elisa L,Lindfors Rossi ^[1] ; Carlo,Finelli ^[4] ; Elisa,Cerqui ^[5] ; Tiziana,Ottone ^[1] ; Alfredo,Molteni ^[6] ; Matteo,Parma ^[7] ; Stella,Santarone ^[8] ; Anna,Candoni ^[9] ; Simona,Sica ^[3] ; Giuseppe,Leone ^[3] ; Francesco,Lo-Coco ^[10] ; Maria Teresa,Voso ^[11]

作者单位： Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy. ^[1] Fondazione GIMEMA, Roma, Italy. ^[2] Dipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy. ^[3] Department of Hematology, Ospedale Sant'Orsola Malpighi, University of Bologna, Bologna, Italy. ^[4] Department of Hematology, A.O. Spedali Civili, Brescia, Italy. ^[5] Department of Hematology, Ospedale Niguarda, Milano, Italy. ^[6] Department of Hematology, HSCT Adult Unit, San Gerardo Hospital, Monza, Italy. ^[7] Department of Hematology, Centro Trapianti Midollo Osseo, Pescara, Italy. ^[8] Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy. ^[9] Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy.;Fondazione Santa Lucia, Laboratorio di Neuro-Oncoematologia, Roma, Italy. ^[10] Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy. voso@med.uniroma2.it. ^[11]